Search

Displaying results 4371 - 4380 of 6951 in total
  1. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this … Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405].

  2. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    However, there currently are no clinical indications for preferential use of ridogrel over aspirin. … Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  3. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

  4. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency

  5. Drug

    GMK

    go.drugbank.com/drugs/DB06661
    Experimental

    GMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma

  6. Drug

    Morinamide

    go.drugbank.com/drugs/DB13417
    Investigational

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  7. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  8. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.

    Categories: Serotonin Receptor Agonists, Serotonin 2c Receptor Agonists
  9. Drug

    Ecabet

    go.drugbank.com/drugs/DB05265
    Investigational

    Ecabet is a prescription eye drop for the treatment of dry eye syndrome. … Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.

  10. Drug

    Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

    go.drugbank.com/drugs/DB15729
    Investigational

    Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.